IP Library Granted Patent US 12,227,519
Granted Patent B2
US 12,227,519 · App. 17/310,941 · Granted Feb 18, 2025

Preparation of maytansinol

Inventors: John Fitzgerald Traverse (Lebonon, NJ); Nareshkumar Jain (Flemington, NJ); Srinath Thirumalairajan (Bensalem, PA); Sanjeevani Ghone (Plainsboro, NJ)
Assignee: CELGENE CORPORATION
C07D498/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,519
App. No.
17/310,941
Granted
Feb 18, 2025
Kind
B2
Abstract

A scaled process of preparing maytansinol, FORMULA II, is provided by reacting a compound of Formula I, wherein R is selected from the group consisting essentially of alkyl, branched alkyl, aryl, alkenyl, alkynyl, as well as substituted variations thereof, with at least one organometallic reagent to produce the compound of Formula II; and, isolating the compound of Formula II.

Claims (12)

1. A method of preparing a compound of Formula II

comprising reacting, in a polar aprotic ethereal solvent, a compound of Formula I, wherein R is selected from the group consisting of alkyl, branched alkyl, aryl, alkenyl, alkynyl, as well as substituted carbon or heteroatom containing alkyl, branched alkyl, aryl, alkenyl or alkynyl, with at least one organometallic reagent to produce the compound of Formula II; and, isolating the compound of Formula II.

2. The method according to claim 1 wherein the compound of Formula I is provided from ansamitocins.

3. The method according to claim 2 wherein the compound of Formula I is provided as Ansamitocin P-3 (AP-3).

4. The method according to claim 1 wherein the organometallic reagent is an organomagnesium reagent.

5. The method according to claim 4 wherein the organometallic reagent is selected from the group consisting of methyl magnesium halide, ethyl magnesium halide, propyl magnesium halide, butyl magnesium halide, and hexyl magnesium halide, where the halide is chloride, bromide, or iodide.

6. The method according to claim 5 wherein the organometallic reagent comprises magnesium bromide.

7. The method according to claim 6 wherein the organometallic reagent is methyl magnesium bromide.

8. The method according claim 1 wherein the organometallic reagent is a nucleophilic organometallic reagent.

9. The method according to claim 8 wherein the nucleophilic organometallic reagent is selected from the group-consisting of organocuprate, methyl-lithium, ethyl-lithium, n-butyl-lithium, hexyl-lithium and alkylaluminum reagents.

10. The method according to claim 1 , wherein the polar aprotic ethereal solvent is selected from the group consisting of 1,4-dioxane, diethyl ether, cyclopropylmethyl ether, cyclopentylmethyl ether, dimethoxyethane, methyl tert-butyl ether, diglyme, tetrahydropyran and 2-methyltetrahydrofuran.

11. The method according to claim 9 , wherein the nucleophilic organometallic reagent is trimethylaluminum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2021
From: TRAVERSE, JOHN FITZGERALD; JAIN, NARESHKUMAR; THIRUMALAIRAJAN, SRINATH; GHONE, SANJEEVANI
To: CELGENE CORPORATION
Reel/Frame 057608/0404 →
Continuity (2)
Provisional Application 62812379 · Mar 1, 2019
Related Publication 20220162230A1 · May 26, 2022
References Cited (9)
US 4308269A · Miyashita et al. · 1981 [cited by applicant]
US 4362663A · Kida et al. · 1982 [cited by applicant]
US 6333410B1 · Chari et al. · 2001 [cited by applicant]
US 7411063B2 · Widdison et al. · 2008 [cited by applicant]
WO 2002016368A1 · 2002 [cited by applicant]
WO 2016061718A1 · 2016 [cited by applicant]
Asai M et al, “Isolation, chemical characterization and structure of ansamitocin, a new antitumor ansamycin antibiotic”, Jan. 1, 1979, vol. 35, No. 9, p. 1079-1085. [cited by applicant]
Wayne C. Widdison et al, “Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer”, Journal of Medicinal Chemistry, vol. 49, No. 14, Jul. 1, 2006, p. 4392-4408. [cited by applicant]
Kupchan S M et al, “Structural Reqirements for Antileukemic Activity among the Naturally Occurring and Semisynthetic Maytansinoids”, Journal of Medicinal Chemistry, American Chemical Society, US, vol. 21, No. 1, Jan. 1,… [cited by applicant]